[1]OTT JJ, STEVENS GA, GROEGER J, et al.Global epidemiology of hepatitis B virus infection:new estimates of age-specific HBs Ag seroprevalence and endemicity[J].Vaccine, 2012, 30 (12) :2212-2219.
|
[2]CHOO SP, TAN WL, GOH BK, et al.Comparison of hepatocellular carcinoma in Eastern versus Western populations[J].Cancer, 2016, 122 (22) :3430-3446.
|
[3]SARIN SK, KUMAR M, LAU GK, et al.Asian-Pacific clinical practice guidelines on the management of hepatitis B:a 2015 update[J].Hepatol Int, 2016, 10 (1) :1-98.
|
[4]TERRAULT NA, BZOWEJ NH, CHANG KM, et al.AASLDguidelines for treatment of chronic hepatitis B[J].Hepatology, 2016, 63 (1) :261-283.
|
[5]European Association for the Study of the Liver.EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection[J].J Hepatol, 2017, 67 (2) :370-398.
|
[6]ILOEJE UH, YANG HI, SU J, et al.Predicting cirrhosis risk based on the level of circulating hepatitis B viral load[J].Gastroenterology, 2006, 130 (3) :678-686.
|
[7]CHEN CJ, YANG HI, SU J, et al.Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level[J].JAMA, 2006, 295 (1) :65-73.
|
[8]LIAW YF, SUNG JJ, CHOW WC, et al.Lamivudine for patients with chronic hepatitis B and advanced liver disease[J].N Engl JMed, 2004, 351 (15) :1521-1531.
|
[9]SHERMAN RE, ANDERSON SA, DAL PAN GJ, et al.Realworld evidence-what is it and what can it tell us?[J].N Engl JMed, 2016, 375 (23) :2293-2297.
|
[10]SUN J, XIE Q, TAN D, et al.The 104-week efficacy and safety of telbivudine-based optimization strategy in chronic hepatitis Bpatients:a randomized, controlled study[J].Hepatology, 2014, 59 (4) :1283-1292.
|
[11]SUN J, MA H, XIE Q, et al.Response-guided peginterferon therapy in patients with HBe Ag-positive chronic hepatitis B:a randomized controlled study[J].J Hepatol, 2016, 65 (4) :674-682.
|